• Lexeo outlined a cardiac gene therapy strategy built around its AAVrh10 capsid, citing ~1.5x to 2x higher heart biodistribution than AAV9.
• LX2006 in Friedreich ataxia cardiomyopathy targets pivotal study initiation in Q2 2026, topline data in 2H 2027, potential BLA in 1H 2028.
• SUNRISE-FA 2 planned as open-label with untreated control; 26 participants; primary endpoint LVMI by cardiac MRI at 6 months; dose 1.2x10^12 vg/kg.
• Phase I/II LX2006 update showed 18% mean LVMI reduction at 6 months in patients with abnormal baseline LVMI; 28% in higher-dose cohorts.
• LX2020 in PKP2 arrhythmogenic cardiomyopathy guided to a 12-month high-dose data update in Q4 2026, with regulatory engagement expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.